InMed Pharmaceuticals (INM) Interest Coverage Ratio (2022 - 2026)
InMed Pharmaceuticals' (INM) quarterly Interest Coverage Ratio came in at 5.45 in Q1 2026, down 156.72% year-on-year from 9.61 in Q1 2025, and up 94.96% quarter-over-quarter from 108.16 in Q4 2025.
InMed Pharmaceuticals (INM) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
InMed Pharmaceuticals' Interest Coverage Ratio history runs 5 years deep, the most recent figure standing at 5.45 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio fell 156.72% year-over-year to 5.45 in Q1 2026; TTM through Mar 2026 was 20.22, a 129.08% decrease from a year earlier, with the FY2025 full-year figure at 9.86, up 77.81% from the prior year.
- Interest Coverage Ratio rose to 5.45 in Q1 2026 per INM's latest filing, from 108.16 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 12.9 in Q2 2024 and bottomed at 123.4 in Q2 2025.
- The 5-year median for Interest Coverage Ratio is 2.35 (2023), against an average of 16.44.
- Across the five-year window, Interest Coverage Ratio soared 1621.28% in 2023 and plunged 4758.79% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 3.63 in 2022, then soared by 63.85% to 1.31 in 2023, then slumped by 69.52% to 2.23 in 2024, then plunged by 4758.79% to 108.16 in 2025, then surged by 94.96% to 5.45 in 2026.
- Per Business Quant, the three latest INM Interest Coverage Ratio figures stand at 5.45 (Q1 2026), 108.16 (Q4 2025), and 2.38 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - | -5.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.45 |
| Dec 31, 2025 | -108.16 |
| Sep 30, 2025 | -2.38 |
| Jun 30, 2025 | -123.40 |
| Mar 31, 2025 | -2.12 |
| Dec 31, 2024 | -2.23 |
| Sep 30, 2024 | -7.91 |
| Jun 30, 2024 | 12.90 |
| Mar 31, 2024 | -1.68 |
| Dec 31, 2023 | -1.31 |
| Sep 30, 2023 | -2.32 |
| Jun 30, 2023 | 5.31 |
| Mar 31, 2023 | -13.71 |
| Dec 31, 2022 | -3.63 |
| Sep 30, 2022 | -6.64 |
| Jun 30, 2022 | -0.35 |